Literature DB >> 8468475

Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog.

W A Kuziel1, G Ju, T A Grdina, W C Greene.   

Abstract

Binding of IL-2 to the high affinity IL-2R results in the formation of a stable complex consisting of IL-2 and at least three distinct, noncovalently associated receptor subunits: IL-2R alpha (p55), IL-2R beta (p70-75), and IL-2R gamma (p64). Ligand binding also stimulates the rapid endocytosis of this receptor complex. To gain further insight into the function of the various subunits of the multicomponent high affinity IL-2R complex, we have carried out binding, internalization, and proliferation assays using an IL-2 analog designated F42A that contains a single Phe for Ala amino acid substitution at position 42. This mutation markedly reduces the intrinsic affinity of the resultant IL-2 analog for the low affinity IL-2R alpha subunit although having little or no effect on binding to the IL-2R beta (or IL-2R beta/gamma) intermediate affinity receptor. We have confirmed that F42A does not bind to the IL-2R alpha chain when expressed alone on MT-1 cells or in the presence of the large or small excess of IL-2R beta chains present on either YT-1 cells or forskolin-induced YT-1 cells, respectively. However, although F42A does not interact with the large number of low affinity IL-2R alpha chains present on HUT 102B2 cells, this ligand does bind to the small number of IL-2R beta chains present on these cells with at least 10-fold higher than expected affinity. These findings indicate that excess IL-2R alpha chains may exert positive effects on binding perhaps by changing the conformation of IL-2R beta. In F42A-stimulated internalization assays on forskolin-induced YT-1 cells, the IL-2R alpha chain is consistently endocytosed together with the IL-2R beta subunit indicating that IL-2R alpha is stably associated with the F42A-IL-2R beta complex even though the alpha-subunit contributes little if any affinity to the F42A binding reaction. In proliferation assays on mouse IL-3-dependent pro-B BA/F3 cells stably coexpressing transfected human IL-2R alpha and IL-2R beta subunits (but a mouse IL-2R gamma subunit), F42A proved to be a more effective agonist of growth than wild-type IL-2. These results suggest that the interaction between wild-type IL-2 but not F42A and the IL-2R alpha subunit in this mixed species high affinity receptor complex may induce an unfavorable receptor conformation leading to diminished rather than enhanced growth signal transduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8468475

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  De novo design of potent and selective mimics of IL-2 and IL-15.

Authors:  Daniel-Adriano Silva; Shawn Yu; Umut Y Ulge; Jamie B Spangler; Kevin M Jude; Carlos Labão-Almeida; Lestat R Ali; Alfredo Quijano-Rubio; Mikel Ruterbusch; Isabel Leung; Tamara Biary; Stephanie J Crowley; Enrique Marcos; Carl D Walkey; Brian D Weitzner; Fátima Pardo-Avila; Javier Castellanos; Lauren Carter; Lance Stewart; Stanley R Riddell; Marion Pepper; Gonçalo J L Bernardes; Michael Dougan; K Christopher Garcia; David Baker
Journal:  Nature       Date:  2019-01-09       Impact factor: 49.962

2.  Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Authors:  Suman Mitra; Aaron M Ring; Shoba Amarnath; Jamie B Spangler; Peng Li; Wei Ju; Suzanne Fischer; Jangsuk Oh; Rosanne Spolski; Kipp Weiskopf; Holbrook Kohrt; Jason E Foley; Sumati Rajagopalan; Eric O Long; Daniel H Fowler; Thomas A Waldmann; K Christopher Garcia; Warren J Leonard
Journal:  Immunity       Date:  2015-05-19       Impact factor: 31.745

3.  Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study.

Authors:  S Damjanovich; L Bene; J Matkó; A Alileche; C K Goldman; S Sharrow; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 4.  Emerging principles of cytokine pharmacology and therapeutics.

Authors:  Robert A Saxton; Caleb R Glassman; K Christopher Garcia
Journal:  Nat Rev Drug Discov       Date:  2022-09-21       Impact factor: 112.288

5.  A versatile design platform for glycoengineering therapeutic antibodies.

Authors:  Seth D Ludwig; Zachary J Bernstein; Christian Agatemor; Kris Dammen-Brower; Jeffrey Ruffolo; Jonah M Rosas; Jeremy D Post; Robert N Cole; Kevin J Yarema; Jamie B Spangler
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

6.  Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits.

Authors:  E Roessler; A Grant; G Ju; M Tsudo; K Sugamura; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  Supplementation with selenium and human immune cell functions. I. Effect on lymphocyte proliferation and interleukin 2 receptor expression.

Authors:  M Roy; L Kiremidjian-Schumacher; H I Wishe; M W Cohen; G Stotzky
Journal:  Biol Trace Elem Res       Date:  1994 Apr-May       Impact factor: 3.738

8.  Enhancement of human lymphocyte proliferative response to purified protein derivative by an anti-interleukin-2 receptor alpha chain antibody (CD25).

Authors:  W Kasinrerk; O Majdic; K Praputpittaya; N Sittisombut
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

9.  Facile discovery of surrogate cytokine agonists.

Authors:  Michelle Yen; Junming Ren; Qingxiang Liu; Caleb R Glassman; Timothy P Sheahan; Lora K Picton; Fernando R Moreira; Arjun Rustagi; Kevin M Jude; Xiang Zhao; Catherine A Blish; Ralph S Baric; Leon L Su; K Christopher Garcia
Journal:  Cell       Date:  2022-03-23       Impact factor: 66.850

10.  Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.

Authors:  Jamie B Spangler; Eleonora Trotta; Jakub Tomala; Ariana Peck; Tracy A Young; Christina S Savvides; Stephanie Silveria; Petra Votavova; Joshua Salafsky; Vijay S Pande; Marek Kovar; Jeffrey A Bluestone; K Christopher Garcia
Journal:  J Immunol       Date:  2018-08-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.